28008561|t|Endpoints for screening thyroid cancer in the Republic of Korea: thyroid specialists ' perspectives
28008561|a|Cancer screening is aimed primarily at reducing deaths from the specific cancer. Thyroid-specific cancer mortality may be the most ambitious endpoint for obtaining estimates of screening effect. Numerous observations have accumulated over the years, indicating that thyroid cancer mortality endpoint has been difficult to study and is confounded by population heterogeneity, provision of randomization, and requirement of large cohorts with sufficiently long follow-up due to the excellent prognosis of the cancer. Accordingly, it may be important to reconsider how to best measure thyroid cancer screening efficacy. Recommendations against thyroid cancer screening should be based upon trials designed to evaluate its effectiveness not only in significant reduction in cancer mortality, but also of other distinct endpoint s. It is desirable to evaluate derivative endpoints that can reliably predict reductions in mortality. The term "derivative" means a variable that is related to the true endpoint and is likely to be observable before the primary endpoint. Derivative endpoints may include thyroid cancer incidence, the proportion of early-stage tumors detected, more treatable stage, the identification of small tumors (to maintain in observation), decrease in the number of people who develop metastatic disease, the increased chance of lesser extent surgery, and the application of minimally invasive approaches, as well as no need for lifelong thyroid replacement therapy, a consistent follow-up, low-dose or no RAI administration and risk factor assessments where case findings should be continuous. The Korean guidelines for thyroid cancer national-level screening were published by a relevant group of multidisciplinary thyroid experts. It was concluded that the evidence is insufficient to balance the benefits and harms of thyroid cancer screening. However, the paper seems to raise the necessary investments in future research and demand a complete analysis for derivative endpoints, and offer screening participants with complete information necessary to make decisions that will provide them with the most value when a small thyroid cancer is screen- identified.
28008561	0	9	Endpoints	T080	C2349179
28008561	14	23	screening	T060	C0199230
28008561	24	38	thyroid cancer	T191	C0549473
28008561	46	63	Republic of Korea	T083	C0022773
28008561	65	72	thyroid	T023	C0040132
28008561	73	84	specialists	T097	C1611835
28008561	87	99	perspectives	T041	C0030971
28008561	100	116	Cancer screening	T060	C0199230
28008561	139	147	reducing	T080	C0392756
28008561	148	154	deaths	T033	C1306577
28008561	173	179	cancer	T191	C0006826
28008561	181	204	Thyroid-specific cancer	T191	C0549473
28008561	205	214	mortality	T081	C0681679
28008561	241	249	endpoint	T080	C2349179
28008561	264	273	estimates	T081	C0750572
28008561	277	286	screening	T058	C1710032
28008561	287	293	effect	T080	C1280500
28008561	295	303	Numerous	T081	C0439064
28008561	304	316	observations	T060	C1964257
28008561	322	333	accumulated	T033	C4055506
28008561	366	380	thyroid cancer	T191	C0549473
28008561	381	390	mortality	T081	C0681679
28008561	391	399	endpoint	T080	C2349179
28008561	409	418	difficult	T080	C0332218
28008561	449	473	population heterogeneity	T102	C0086833
28008561	475	484	provision	T058	C1283218
28008561	488	501	randomization	T062	C0034656
28008561	507	518	requirement	T169	C1514873
28008561	528	535	cohorts	T098	C0599755
28008561	554	568	long follow-up	T058	C1517942
28008561	580	589	excellent	T080	C1961136
28008561	590	613	prognosis of the cancer	T201	C1516221
28008561	638	647	important	T080	C3898777
28008561	682	696	thyroid cancer	T191	C0549473
28008561	697	706	screening	T060	C0199230
28008561	707	715	efficacy	T080	C1280519
28008561	717	732	Recommendations	T078	C0034866
28008561	741	755	thyroid cancer	T191	C0549473
28008561	756	765	screening	T060	C0199230
28008561	819	832	effectiveness	T080	C1280519
28008561	845	866	significant reduction	T080	C0392756
28008561	870	876	cancer	T191	C0549473
28008561	877	886	mortality	T081	C0681679
28008561	915	923	endpoint	T080	C2349179
28008561	966	975	endpoints	T080	C2349179
28008561	1002	1025	reductions in mortality	T081	C0282251
28008561	1094	1102	endpoint	T080	C2349179
28008561	1153	1161	endpoint	T080	C2349179
28008561	1174	1183	endpoints	T080	C2349179
28008561	1196	1210	thyroid cancer	T191	C0549473
28008561	1211	1220	incidence	T081	C0021149
28008561	1226	1236	proportion	T081	C1709707
28008561	1240	1251	early-stage	T079	C2363430
28008561	1252	1258	tumors	T191	C0027651
28008561	1259	1267	detected	T033	C0442726
28008561	1274	1289	treatable stage	T201	C1300072
28008561	1295	1309	identification	T080	C0205396
28008561	1313	1325	small tumors	T080	C0475277
28008561	1356	1388	decrease in the number of people	T058	C0509797
28008561	1401	1419	metastatic disease	T191	C0027627
28008561	1425	1434	increased	T081	C0205217
28008561	1459	1466	surgery	T061	C0543467
28008561	1491	1520	minimally invasive approaches	T169	C2711297
28008561	1545	1553	lifelong	T079	C4274169
28008561	1554	1581	thyroid replacement therapy	T061	C2242640
28008561	1585	1595	consistent	T078	C0332290
28008561	1596	1605	follow-up	T058	C1522577
28008561	1607	1615	low-dose	T081	C0445550
28008561	1622	1640	RAI administration	T060	C0203778
28008561	1645	1668	risk factor assessments	T170	C2983699
28008561	1675	1688	case findings	T058	C1444481
28008561	1699	1709	continuous	T078	C0549178
28008561	1715	1721	Korean	T098	C1556095
28008561	1715	1732	Korean guidelines	T170	C0162791
28008561	1737	1751	thyroid cancer	T191	C0549473
28008561	1752	1766	national-level	T082	C0681788
28008561	1767	1776	screening	T058	C0220908
28008561	1815	1848	multidisciplinary thyroid experts	T060	C0729737
28008561	1876	1900	evidence is insufficient	T169	C3858734
28008561	1916	1924	benefits	T081	C0814225
28008561	1938	1952	thyroid cancer	T191	C0549473
28008561	1953	1962	screening	T060	C0199230
28008561	2034	2042	research	T062	C0035168
28008561	2056	2064	complete	T080	C0205197
28008561	2065	2073	analysis	T062	C0936012
28008561	2089	2098	endpoints	T080	C2349179
28008561	2110	2119	screening	T058	C0220908
28008561	2120	2132	participants	T098	C0679646
28008561	2147	2158	information	T078	C1533716
28008561	2169	2186	to make decisions	T041	C0679006
28008561	2243	2257	thyroid cancer	T191	C0549473
28008561	2269	2279	identified	T080	C0205396